Orforglipron: the new oral GLP-1

Orforglipron is the first oral small molecule GLP-1 receptor agonist approved for weight management. It reached the market in 2026 under the brand name Foundayo, from Eli Lilly.

It is new enough that the honest framing is: the trial evidence is real and published, and the long term real world record does not exist yet, because there has not been time.

What makes it different

The established GLP-1 medicines are peptides. Peptides are fragile in the digestive tract, which is why semaglutide and tirzepatide are injected. There is an oral semaglutide, and it comes with particular administration requirements because of that fragility.

Orforglipron is a small molecule, not a peptide. That is a chemistry difference rather than a delivery trick, and it is the reason it can be a daily tablet.

The practical consequence is that a daily pill removes the injection barrier, which for some people is the whole reason they have not started.

What the trials found

The evidence is published and substantial for a new medicine.

• Daily oral orforglipron for adults with obesity, New England Journal of Medicine, 2023
• Orforglipron for obesity treatment, New England Journal of Medicine, 2025
• ATTAIN-2, a phase 3 randomised, double blind, multicentre, placebo controlled trial in people with obesity and type 2 diabetes, The Lancet, 2025
• Earlier phase 2 dose response work in type 2 diabetes, The Lancet, 2023

For context, the 2025 meta-analysis of this drug class put tirzepatide 15 mg at 17.8 percent average weight loss at 72 weeks and semaglutide 2.4 mg at up to 13.9 percent at 68 weeks. Where orforglipron sits against those over the long term is the question the next few years will answer, and we are not going to guess at it here.

The approval itself was unusual

The FDA approved Foundayo under the Commissioner's National Priority Voucher pilot programme, 50 days after filing. The agency described it as the fastest approval of a new molecular entity since 2002.

That is worth understanding rather than being alarmed by. A priority voucher speeds up the FDA's review clock. It does not remove the requirement for trial evidence, and the trials above were completed and published before approval.

What it does mean is that the accumulated real world experience is smaller than for a medicine that has been in wide use for years. That is simply a function of time.

The boxed warning

Foundayo carries a boxed warning for thyroid C-cell tumours. It should not be used by people with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2.

This is consistent with the rest of the class. Semaglutide and tirzepatide products carry the same warning and the same contraindications.

Side effects

As a GLP-1 receptor agonist, the expected profile is the class profile, dominated by gastrointestinal effects during dose escalation. Across the class, gastrointestinal events were reported by 47 to 84 percent of trial participants against 13 to 63 percent on placebo.

The specific rates for orforglipron are in its own trial publications and its label, and a clinician prescribing it should walk you through those rather than the class averages.

Cost and coverage

Foundayo is one of the products named by CMS under the Medicare GLP-1 Bridge, the demonstration running 1 July 2026 to 31 December 2027, at fifty dollars a month for eligible Part D beneficiaries.

The fine print applies here as it does to the others: the Part D deductible does not apply, the fifty dollars does not count toward your true out of pocket total, and there is no low income subsidy attached.

One thing that has not changed

It cannot be compounded. Compounding requires a lawful basis, and for a newly approved product with no shortage there is none. If anyone offers you a compounded or "research" version of orforglipron, that is not a grey area.

The same is true of retatrutide and cagrilintide, two molecules that have never been FDA approved for anything and therefore have no lawful compounding route at all.

The honest summary

A daily oral GLP-1 that removes the injection barrier is a genuine change for people who would not start an injectable. The trial evidence is published and was reviewed before approval.

What does not exist yet is years of real world use, head to head trials against the leading injectables, or long term discontinuation data specific to this molecule. When those arrive we will update this page and date the change.

What to ask

• Is orforglipron appropriate for me given my history, particularly any thyroid history?
• How does it compare to an injectable for my specific situation?
• What are the side effect rates from its own trials, not the class averages?
• Am I eligible for the Medicare GLP-1 Bridge?
• What is known about what happens if I stop?

Sources

• FDA, approval of Foundayo (orforglipron) tablets, NDA 220934, product label
• FDA, press announcement on the Commissioner's National Priority Voucher programme approval
• Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2302392
• Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2511774
• Orforglipron for obesity in people with type 2 diabetes (ATTAIN-2), phase 3 trial. The Lancet, 2025. doi:10.1016/s0140-6736(25)02165-8
• Efficacy and safety of GLP-1 receptor agonists for weight management, systematic review and meta-analysis, 2025
• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge

How we verify: see /how-we-verify.

Keep reading

How the two leading injectable molecules compare, at /guides/semaglutide-vs-tirzepatide.

Why some molecules cannot be compounded at all, at /guides/grey-market-semaglutide.